AHA Advocacy Alliance for the 340B Discount Drug Program
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to tax-payer supported health care facilitates that care for uninsured and low-income people. Participating hospitals depend on the 340B drug discount program to provide pharmacy services to some of their most vulnerable patients. The AHA 340B Advocacy Alliance seeks to promote the value that this program provides to patients and communities and fight any efforts to scale back the program. In addition, the alliance will advocate for extending the 340B discounts to the purchases of drugs used during inpatient hospital stays; the expansion of the program would be a win-win for taxpayers and hospitals.
TOOLS AND RESOURCES |
RESOURCES
- AHA Comments to HRSA on 340B Drug Discount Program
- Audio Recording of March 28 Call on HRSA 340B Audits
- Action Alert on Letters to HRSA Outlining Challenges with 340B GPO Notice
- Action Alert on 340B GPO prohibition notice
- Audio Recording of March 7 AHA 340B Call with HRSA Leaders on GPO Prohibition Guidance
- AHA to host call with HRSA leaders on new 340B GPO prohibition guidance
- HRSA Posts Some 340B Audit Results
- Factsheet: 340B Drug Discount Program
- AHA 340B Conference Call with HRSA leaders on December 18, 2012
- Legislation introduced would weaken 340B
- AHA 340B Conference Call: February 7, 2013
- 2012 AHA Advocacy Issue Paper
- 340B Program Expansion
- Comment Letter: Exclusion of Orphan Drugs for Certain Covered Entities Under 340B Program
- AHA Testimony: Expiring Medicare Provider Payment Provisions
- Pharmacy Affairs & 340B Drug Pricing Program
- HRSA FAQs on 340B Program
AHA NEWS
340B IN THE NEWS